VivEye – The promise of
long-lasting relief
VivEye is an innovative non-invasive therapy designed to treat the ocular surface and tear film, for long-lasting relief of signs & symptoms of Dry Eye Disease.
EpiTech’s proprietary technology is based on magnetic neurostimulation of the ocular area, resulting in the reinforcement of the structural integrity of the ocular surface. The VivEye is designed for comfortable and ergonomic positioning for the treated subject, the procedure is well-tolerated, non-invasive, and takes 10 minutes per eye.
Clinical studies have showed that the VivEye is safe and effective, providing significant improvement for moderate to severe Dry Eye Disease patients.
The painful story of Dry Eye Disease
Dry Eye Disease is no small irritation. For millions of patients it causes daily agony manifested by sensitivity to bright lights, stabbing pain, a sensation of gritty sand in the eye, blurry vision, and in some cases severe vision impairment. In fact, 20% of the adult population worldwide report a real and substantial impairment of quality of life associated with their dry eye disease.
people in the US use pharmaceutical treatments,
usually with very low compliance or efficacy
of ophthalmologists desire better treatment options for their patients
Clinical study results show improvement in signs and symptoms of Dry Eye Disease
First in Human study results (29 subjects, 43 treated eyes)
- Safety: No noted changes in any safety-related parameters, including intra-ocular pressure, visual acuity or slit lamp findings.
- Corneal staining: Significant reduction (improvement) in corneal staining during the course of the study, which lasted up to 12 weeks post treatment.
- Symptoms: Subjects reported an improvement in dry eye symptoms, from one day following VivEye treatment, and up to 12 weeks post treatment.
Case study
G.K., a 47-year-old male, had severe dry eye disease symptoms and abundant Superficial Punctate Keratitis (SPKs). Significant reduction in SPKs was observed in the treated eye, at 4 and 8 weeks post-treatment, with parallel improvement in dry eye symptoms.
Baseline
Abundant SPKs
4 weeks post-treatment
Scarce SPKs
8 weeks post-treatment
Scarce SPKs
One month after one of my eyes was treated, I woke up with one non-dry eye. After 12 weeks the treated eye was still much less dry, less red, and burned less. After both my eyes were treated, I had a significant reduction in my daily symptoms and dry eye sensation
After one of my eyes was treated, I sent a picture of both eyes to the doctor; the treated eye was normal, while the other stayed red. People used to make jokes and say that I looked intoxicated, now they joked that it was only for one eye. The effect was even larger afterwards, when both my eyes were treated. I was always bothered by the constant discharge in my eyes, it felt like strings were attached to my eyelids and eyelashes… now all of that is gone… I even went back to wearing make-up, and can finally work on a computer.
I had tried many things beforehand and was very skeptical about the device. Two days after the treatment my life had changed; I could finally stay in air-conditioned rooms and needed much less eyedrops.
Efficiently relieving dry eye symptoms
Long lasting
dry eye relief
Non-invasive
& no contact
In-office
treatment
Can be administered
regardless of
of DED etiology
Easy to comply
Proven safety
Latest news
EpiTech Completes Enrolment to its Pilot Trial
The company has met its goal of enrolling 50 subjects by the end of January 2021.
Three new Medical Centers Join as Enrolling Sites in EpiTech’s 2nd multicenter clinical trial
EpiTech is proud to welcome Hadassah, Rabin and HaEmek Medical Centers as enrolling sites in pilot study
About us
EpiTech Mag Ltd. was incorporated in Israel in 2015, originally founded out of the TerraLab Ventures Incubator. The company has a solid intellectual property portfolio in the field of ocular neurostimulation and is led by a seasoned team of technological and clinical veterans, with leading KOLs in advisory roles.